# US 2023/0057482 A1 · Engineered crispr-cas systems and methods for sensitive and specific diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057482 A1
- Document ID: US20230057482A1
- Status: Published application
- Kind: A1
- Application number: 17/814,674
- Filed: 2022-07-25
- Published: 2023-02-23
- Earliest claimed: 2020-04-27
- Assignees: Montana State University
- Applicants: Montana State University
- Inventors: Blake A. WIEDENHEFT; Andrew SANTIAGO-FRANGOS; Anna A. NEMUDRAIA; Artem A. NEMUDRYI
- Web page: https://patentgrep.com/patent/US20230057482A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12Q 1/701: {Specific hybridization probes}
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/1131: {against viruses}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosure relates to an engineered type III CRISPR-Cas system for sensitive and sequence specific detection of nucleic acid in a sample. For example, the engineered type III CRISPR-Cas system may be implemented as an assay for testing SARS-CoV-2 virus (or other target nucleic acid in the sample) that can be performed quickly, such as in one hour or less. Nucleic acid recognition by type III systems may trigger Cas10-mediated nuclease activity and/or polymerase activity, which may generate pyrophosphates, protons and cyclic oligonucleotides. The nuclease activity and/or the one or more products of the Cas10-polymerase are detected using colorimetric, visible fluorometric, and/or instrumented fluorometric detection.

## Claims

### Claim 1

A method of detecting nucleic acid in a sample, comprising:
contacting the sample with an engineered type III Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas system to detect NA in the sample, the engineered CRISPR-Cas system comprising:
a CRISPR guide comprising a CRISPR guide sequence that is complementary to a locus of the nucleic acid;
a first subunit that undergoes a conformational change upon binding of the engineered type III CRISPR-Cas system to the locus of the nucleic acid, the conformational change activating DNase activity of the first subunit and/or polymerase activity of the first subunit, the polymerase activity generating one or more products; and
detecting the DNase activity and/or the one or more products of the polymerase activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nucleic acid comprises a viral ribonucleic acid (RNA).

### Claim 3 (depends on 2)

The method of claim 2, wherein the viral RNA comprises RNA of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

### Claim 4 (depends on 3)

The method of claim 3, wherein the locus comprises a nucleocapsid gene (N-gene) of the SARS-CoV-2.

### Claim 5 (depends on 3)

The method of claim 3, wherein the locus comprises a region of the viral RNA that is conserved among a plurality of SARS-CoV-2 genomes.

### Claim 6 (depends on 2)

The method of claim 2, wherein the CRISPR guide sequence comprises a nucleic acid sequence of SEQ ID NO. 1.

### Claim 7 (depends on 2)

The method of claim 2, wherein the CRISPR guide sequence comprises a nucleic acid sequence of SEQ ID NO. 2.

### Claim 8 (depends on 1)

The method of claim 1, wherein the one or more products comprise a linear or cyclic oligonucleotide and wherein the detection system comprises instrumented fluorometric detection comprising:
an RNA tether linking a fluorophore to a quencher; and
a nuclease activated by the linear or cyclic oligonucleotide, the activated nuclease cleaving the RNA tether to thereby release the fluorophore that is detected by a fluorescence detecting instrument.

### Claim 9 (depends on 8)

The method of claim 8, wherein the linear or cyclic oligonucleotide comprises a cyclic oligoadenylate, and wherein the nuclease activated by the linear or cyclic oligonucleotide comprises Csm6 or Can1.

### Claim 10 (depends on 8)

The method of claim 8, wherein the instrumented fluorometric detection further comprises:
a deoxyribonucleic acid (DNA) tether linking the fluorophore or a second fluorophore to the quencher or a second quencher,
wherein the DNase activity cleaves the DNA tether to thereby release the fluorophore or the second fluorophore.

### Claim 11 (depends on 1)

The method of claim 1, wherein the detection system comprises instrumented fluorometric detection comprising:
a deoxyribonucleic acid (DNA) tether linking a fluorophore to a quencher,
wherein the first subunit has a DNase activity that is activated upon hybridization of the RNA guide to the locus of the viral RNA, the DNase activity cleaving the DNA tether to thereby release the fluorophore that is detected.

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more products comprise a linear or cyclic oligonucleotide and wherein the detection system comprises instrumented fluorometric detection comprising:
a deoxyribonucleic acid (DNA) tether linking a fluorophore to a quencher; and a nuclease activated by the linear or cyclic oligonucleotide, the activated nuclease cleaving the DNA tether to thereby release the fluorophore that is detected by a fluorescence detecting instrument.

### Claim 13 (depends on 1)

The method of claim 1, wherein the one or more products comprise a pyrophosphate, and wherein the detection system comprises visible fluorometric detection comprising:
a fluorescent dye quenched by a quencher;
wherein the pyrophosphate forms an insoluble precipitate with the quencher to thereby unquench the fluorescent dye that is detected based on a color change.

### Claim 14 (depends on 13)

The method of claim 13, wherein the fluorescent dye comprises calcein and the quencher comprises Manganese, and wherein unquenched calcein is bound by Magnesium to form a fluorescent complex that is detected.

### Claim 15 (depends on 1)

The method of claim 1, wherein the one or more products comprise protons, and wherein the detection system comprises a colorimetric system, the colorimetric system comprising:
a solution comprising a pH-sensitive dye; and
wherein the protons acidify the solution, resulting in a change in color of the pH-sensitive dye.

### Claim 16 (depends on 1)

The method of claim 1, wherein the engineered type III CRISPR-Cas system further comprises:
an engineered second subunit comprising a backbone subunit of the engineered type III CRISPR-Cas system with an introduced mutation, the engineered second subunit having RNase activity when in wildtype form, but the introduced mutation disrupting the RNase activity to prevent degradation of the viral RNA, thereby increasing signal generation of the detection system.

### Claim 17 (depends on 13)

The method of claim 13, wherein the first subunit comprises a Cas10 subunit, the second subunit comprises Csm3, and wherein an activity of the Cas10 subunit is moderated by activity of the second subunit in the wildtype form, and wherein the introduced mutation to the second subunit disrupts the moderation of the Cas10 subunit.

### Claim 18 (depends on 16)

The method of claim 16, wherein the wildtype form of the second subunit comprises an amino acid sequence of SEQ ID NO. 26 and the second subunit with the introduced mutation comprises an amino acid sequence of SEQ ID NO. 27.

### Claim 19 (depends on 1)

The method of claim 1, wherein the one or more products comprise (i) a linear or cyclic oligonucleotide and (ii) protons, wherein the detection system comprises:
fluorometric detection comprising:
an RNA tether linking a fluorophore to a quencher;
a nuclease activated by the linear or cyclic oligonucleotide, the activated nuclease cleaving the RNA tether to thereby release the fluorophore that is detected; and
colorimetric detection comprising:
a solution comprising a pH-sensitive dye; and
wherein the solution is acidified by the protons resulting in a change in color of the pH-sensitive dye.

### Claim 20 (depends on 19)

The method of claim 19, wherein the fluorometric detection further comprises:
a deoxyribonucleic acid (DNA) tether linking the fluorophore or a second fluorophore to the quencher or a second quencher,
wherein the DNase activity cleaves the DNA tether to thereby release the fluorophore or the second fluorophore.

### Claim 21 (depends on 1)

The method of claim 1, wherein the one or more products comprise protons, wherein the detection system comprises:
fluorometric detection comprising:
a deoxyribonucleic acid (DNA) tether linking a fluorophore to a quencher, wherein the DNase activity cleaves the DNA tether to thereby release the fluorophore that is detected; and
colorimetric detection comprising:
a solution comprising a pH-sensitive dye; and
wherein the solution is acidified by the protons resulting in a change in color of the pH-sensitive dye.

### Claim 22 (depends on 1)

The method of claim 1, wherein the nucleic acid comprises ribonucleic acid (RNA), the system further comprising: a reverse transcription loop-mediated isothermal amplification (RT-LAMP) primer having a T7 binding site for RT-LAMP-T7 amplification of the RNA.

### Claim 23 (depends on 22)

The method of claim 22, wherein the RT-LAMP-T7 amplification and the detection of the RNA comprises a single pot combination.
